Arthus reaction

Jump to: navigation, search
Arthus reaction
ICD-10 T78.4
ICD-9 995.21
DiseasesDB 33220
MeSH D001183

WikiDoc Resources for Arthus reaction

Articles

Most recent articles on Arthus reaction

Most cited articles on Arthus reaction

Review articles on Arthus reaction

Articles on Arthus reaction in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Arthus reaction

Images of Arthus reaction

Photos of Arthus reaction

Podcasts & MP3s on Arthus reaction

Videos on Arthus reaction

Evidence Based Medicine

Cochrane Collaboration on Arthus reaction

Bandolier on Arthus reaction

TRIP on Arthus reaction

Clinical Trials

Ongoing Trials on Arthus reaction at Clinical Trials.gov

Trial results on Arthus reaction

Clinical Trials on Arthus reaction at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Arthus reaction

NICE Guidance on Arthus reaction

NHS PRODIGY Guidance

FDA on Arthus reaction

CDC on Arthus reaction

Books

Books on Arthus reaction

News

Arthus reaction in the news

Be alerted to news on Arthus reaction

News trends on Arthus reaction

Commentary

Blogs on Arthus reaction

Definitions

Definitions of Arthus reaction

Patient Resources / Community

Patient resources on Arthus reaction

Discussion groups on Arthus reaction

Patient Handouts on Arthus reaction

Directions to Hospitals Treating Arthus reaction

Risk calculators and risk factors for Arthus reaction

Healthcare Provider Resources

Symptoms of Arthus reaction

Causes & Risk Factors for Arthus reaction

Diagnostic studies for Arthus reaction

Treatment of Arthus reaction

Continuing Medical Education (CME)

CME Programs on Arthus reaction

International

Arthus reaction en Espanol

Arthus reaction en Francais

Business

Arthus reaction in the Marketplace

Patents on Arthus reaction

Experimental / Informatics

List of terms related to Arthus reaction

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Overview

In immunology, the Arthus reaction is a type of local type III hypersensitivity reaction. Type III hypersensitivity reactions are immune complex mediated, and involve the deposition of an antigen/antibody complex mainly in the vascular walls, serosa (pleura, pericardium, synovium), and glomeruli.

The Arthus reaction was discovered by Arthus in 1903.[1] Arthus repeatedly injected horse serum subcutaneously into rabbits. After four injections, he found that there was edema and that the serum was absorbed slowly. Further injections eventually led to gangrene.

The Arthus reaction involves the in situ formation of antigen/antibody complexes after the intradermal injection of an antigen. If the animal/patient was previously sensitized (has circulating antibody), an Arthus reaction occurs. This manifests as local vasculitis due to deposition of immune complexes in dermal blood vessels. Activation of complement and recruitment of PMNs ensue resulting in an inflammatory response.

Arthus reactions have been infrequently reported after vaccination against diphtheria and tetanus. To quote from the CDC:[2]

Arthus reactions (type III hypersensitivity reactions) are rarely reported after vaccination and can occur after tetanus toxoid–containing or diphtheria toxoid–containing vaccines. An Arthus reaction is a local vasculitis associated with deposition of immune complexes and activation of complement. Immune complexes form in the setting of high local concentration of vaccine antigens and high circulating antibody concentration. Arthus reactions are characterized by severe pain, swelling, induration, edema, hemorrhage, and occasionally by necrosis. These symptoms and signs usually occur 4–12 hours after vaccination.....ACIP has recommended that persons who experienced an Arthus reaction after a dose of tetanus toxoid–containing vaccine should not receive Td more frequently than every 10 years, even for tetanus prophylaxis as part of wound management.

References

  1. Injections répétées de serum du cheval chez le lapin, Comptes rendus des séances de la Société de biologie et de ses filiales, Paris, 55 (1903), 817–820.
  2. Preventing Tetanus, Diphtheria, and Pertussis Among Adolescents: Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccines, K. R. Broder et al., MMWR Recommendations and Reports, March 24, 2006 / 55(RR03), 1–34, page 18.

See also



Linked-in.jpg